OM1: The Real-World Data Powerhouse Transforming Precision Medicine in 2025
Overview: How OM1’s AI‑Driven Real‑World Evidence Platform Transforms Outcomes‑Based Healthcare OM1 is an AI‑enabled real‑world evidence platform that curates and analyses longitudinal clinical data to measure outcomes and generate disease‑specific insights. Within many specialities, especially where outcomes are poorly captured in claims, organisations struggle with fragmented, unstructured EHR data and a lack of timely, high‑quality […]
Feature Categories
Overview: How OM1’s AI‑Driven Real‑World Evidence Platform Transforms Outcomes‑Based Healthcare
OM1 is an AI‑enabled real‑world evidence platform that curates and analyses longitudinal clinical data to measure outcomes and generate disease‑specific insights. Within many specialities, especially where outcomes are poorly captured in claims, organisations struggle with fragmented, unstructured EHR data and a lack of timely, high‑quality real‑world evidence to inform clinical and commercial decisions. OM1 addresses this bottleneck by building disease registries and linked datasets that bring together structured fields, narratives, and other real‑world data into coherent patient journeys aligned to specific therapeutic areas.
On top of these curated datasets, OM1 applies machine learning to standardise outcomes, identify cohorts, and model disease progression or treatment response at scale. This enables more consistent measurement of clinically meaningful endpoints and supports analytics such as comparative effectiveness, safety monitoring, and value demonstration without starting from raw data each time. For clinical and HEOR teams, this can shorten evidence‑generation timelines and reduce the manual effort involved in cleaning and structuring data, while improving confidence in the robustness and reproducibility of study outputs.
Last checked on 07 May 2026: remains an AI‑driven real‑world evidence and outcomes company, with recent launches of PhenOM‑powered products (Orion, Lyra, Polaris) and new clinical validation of its decision support tools.
What is OM1?
OM1 is a real‑world evidence platform that aggregates and curates longitudinal clinical data from electronic health records and other sources to generate disease‑specific outcomes insights. It is used by life sciences researchers and outcomes teams that need structured, specialty‑focused datasets and analytics for studies such as comparative effectiveness, safety, and value demonstration. OM1 is differentiated by its emphasis on speciality disease registries and outcomes measurement, using AI and machine learning to standardise endpoints and model disease progression within specific therapeutic areas.
Why Do Leading Healthcare Teams Trust OM1?
-
Strategic partnerships with organisations such as the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO‑HNSF) and Panalgo, integrating OM1’s speciality datasets and outcomes platforms with established clinical registries and analytics tools.
-
Expansion into Europe with a dedicated presence to support life sciences companies and healthcare organisations with AI‑enhanced real‑world evidence solutions and collaborations with European institutions.
-
OM1’s Real‑World Data Cloud combines clinical data from more than 250–300 million patient records with AI and machine learning to generate research‑grade real‑world evidence, emphasising chronic disease and outcomes measurement.
-
PhenOM, OM1’s AI model trained on billions of patient‑years, is used to predict events, risks, and outcomes, supporting earlier identification of high‑risk patients and more precise cohort selection.
-
OM1’s PremiOM disease‑specific datasets, enriched with standardised clinical endpoints and outcomes, are positioned as “regulatory‑grade” and are distributed via partners such as Panalgo’s IHD platform to support HEOR and RWE studies.
-
Independent industry recognition includes Frost & Sullivan’s 2024 North America New Product Innovation Award in real‑world evidence analytics, highlighting the maturity of OM1’s AI‑enabled RWE solutions.
-
An independent AI‑based evaluation by Cornerstone AI rated OM1’s rheumatoid arthritis dataset “highest quality” on standardisation, correctness, and completeness, providing external validation of data quality.
-
Public materials describe OM1 as operating under healthcare privacy and security regulations, using de‑identified data and positioning its RWD as suitable for regulatory and market access use, indicating a compliance‑oriented data governance approach.
Top 3 Pain Points OM1 Fixes in Healthcare
| Problem | How OM1 Solves It |
|---|---|
| 1. Fragmented, outdated real-world data sources | Provides a unified view of over 300M+ longitudinal lives across care settings |
| 2. Slow, siloed analytics across functions | Enables no-code, GenAI-powered insights via MapLab tools mapAI & mapExplorer for instant collaboration |
| 3. Inadequate evidence generation for trial design or HEOR | Powers cohort building, external control arms, and AI phenotyping with PhenOM to enhance precision at scale |
Feature Category Summary: OM1
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | OM1 describes its Integrated Evidence Generation framework as explicitly aligned to FDA expectations for RWD/RWE, detailing how OM1 Origin connects directly to source EMR systems and labs, how EMR Engine aggregates, de‑identifies, and derives validated structured variables from unstructured notes, and how data traceability (including all transformations) and validation of derived endpoints are “key areas for review in an FDA submission.” Press and partner materials characterize OM1’s PremiOM datasets and platforms as providing “regulatory‑grade evidence” and “regulatory‑grade insights” for submissions, and OM1’s Registries Center of Excellence commits to ensuring that data collection, storage, and analysis “comply with regulations and guidelines” and generate “fit‑for‑purpose” data for regulatory bodies. Although full GxP / 21 CFR Part 11 validation details are not public, there is explicit evidence that OM1 is designed for regulatory‑grade, FDA‑oriented RWE. | YES |
| Clinical Trial Support | OM1 Polaris is marketed as an AI‑driven clinical‑trial recruitment and feasibility solution that uses RWD and protocol‑tailored profiles to “accelerate participant identification, streamline site selection, and reduce recruitment timelines,” with case studies showing improved recruitment in rare and under‑diagnosed diseases and enhanced diversity. White papers and Aspen/registry materials describe automated data collection in prospective studies and registries, support for embedded trials and external comparator arms, and sponsors exploring OM1 systems for passive data collection as a routine part of randomized clinical trials to reduce burden and improve data completeness. These are explicit capabilities for trial feasibility, site selection, recruitment, and operational evidence generation. | YES |
| Supply Chain & Quality | OM1’s offerings focus on real‑world outcomes, registries, phenotyping, and trial recruitment; documentation discusses safety, effectiveness, quality, and value evidence in real‑world settings but in the context of clinical outcomes and payer value rather than GMP manufacturing. No public documentation found that OM1 provides QA for manufacturing, batch release, serialization, or counterfeit detection; its domain is clinical and outcomes evidence, not supply‑chain integrity. | NA |
| Efficiency & Cost-Saving | OM1’s Aspen automated study platform and real‑world data research networks are described as enabling “rapid and scalable real‑world evidence generation” by automating data collection from EHRs, registries, and other sources, significantly reducing site burden compared with traditional manual data entry. Polaris materials emphasize that AI‑driven profiles and RWD can “cut recruitment timelines and reduce trial costs,” while automation and reusable data networks allow sponsors to reuse sites and infrastructure for multiple studies, avoiding redundant setup and reducing per‑study cost and investigator time. These are explicit efficiency and cost‑saving claims. | YES |
| Scalable / Enterprise-Grade | Frost & Sullivan’s 2025 Radar and other analyses identify OM1 as a leading life‑sciences RWE provider with AI‑driven Aspen and large disease‑specific registries, noting that OM1 manages tens of millions of patients’ worth of deep clinical data across multiple specialties. OM1’s Real‑World Data Cloud lists “60 billion rows of data and growing” with a “highly secure, HIPAA‑compliant, customizable, rapidly implementable” advanced cloud platform, and OM1’s expansion into Europe includes collaborations with leading healthcare institutions, regulatory bodies, and biopharma companies, underscoring enterprise deployments. Registries and networks targeting multiple diseases (e.g., rheumatology, cardiology, neurology) further demonstrate scalable, multi‑sponsor infrastructure. | YES |
| HIPAA Compliant | OM1’s platform and applications security page states that “all data we collect is collected in a HIPAA‑compliant manner under appropriate agreements and controls,” and emphasizes strict administrative, physical, and technical safeguards, need‑to‑know access, and AWS infrastructure configured to meet data‑location and security requirements. The LeRHN network page similarly notes that OM1 uses safeguards “in compliance with HIPAA privacy and security standards” when combining practice data with OM1’s intelligent data cloud and ML technologies. These are explicit statements of HIPAA‑compliant data handling. | YES |
| Clinically Validated | OM1’s AI‑enabled PhenOM platform provides digital phenotyping and disease‑severity models validated against structured and unstructured EHR data to define progression, treatment efficacy, and patient outcomes, with Frost & Sullivan highlighting its “sophisticated phenotyping models” and disease‑severity scores used in clinical research. OM1 has published and supported numerous peer‑reviewed outcome and effectiveness studies using its registries and RWD (e.g., in rheumatology and cardiology) for regulatory and payer submissions, but there is no public evidence that OM1’s software itself has received FDA/EMA device clearance as a clinical decision‑support or diagnostic product. Given the lack of explicit regulated‑product clearance, the platform is validated as an evidence‑generation infrastructure rather than as a clinical device. | NA |
| EHR Integration | OM1 Origin is described as a “connecting and sourcing platform” that “connects directly to site EMR and other systems,” using an “extensive library of adapters specific to each site’s EMR instance” to identify sub‑networks and enable reusable sites for evidence generation. OM1’s data‑network info sheet clearly states that OM1 leverages proprietary technology “to integrate with electronic health records (EHRs) and other data sources to clean, normalize, and link patient and specialist data,” and white papers describe EMR Engine consuming data from Origin to create de‑identified longitudinal datasets for analysis. This is explicit EHR integration for data extraction and registry/analytics workflows, even if not embedded as point‑of‑care CDS. | YES |
| Explainable AI | OM1’s technology descriptions emphasize that EMR Engine produces “validated structured variables from unstructured clinical notes,” and PhenOM provides clinically meaningful phenotypes and disease‑severity scores with clear definitions of inputs (diagnoses, labs, medications, symptoms) and derived endpoints used in regulatory submissions. However, public materials do not describe formal explainable‑AI tooling such as feature‑importance dashboards, SHAP/attribution plots, or user‑facing explanations for individual predictions; AI is framed as providing “deeper insights” and validated endpoints, but the transparency mechanisms are not detailed as product features. No public documentation found for explicit, productized explainable‑AI modules. | NA |
| Real-Time Analytics | OM1’s Real‑World Data Cloud emphasizes “advanced cloud platform,” “predictive & prescriptive modeling,” “AI, machine learning, NLP,” and “robust automation,” but does not explicitly advertise continuous real‑time streaming analytics; the focus is on large‑scale, periodically updated datasets and automated study platforms rather than second‑by‑second monitoring. While Origin and Aspen automate near‑real‑time data collection and registry updates from EHRs, descriptions frame this as automated or frequent rather than strict real‑time processing with immediate dashboards. No public documentation found that OM1 provides true real‑time analytics as defined. | NA |
| Bias Detection | OM1 Polaris marketing highlights improving diversity in participant populations and addressing recruitment challenges in under‑diagnosed diseases, and broader industry commentary names OM1 among “regulatory‑grade” platforms attentive to equity in trials. However, available documentation does not describe specific bias‑detection or fairness‑metric modules within PhenOM, Aspen, or Polaris (e.g., monitoring model performance across demographic subgroups); fairness is discussed conceptually at the trial‑design level rather than as an explicit algorithmic bias‑detection feature. No public documentation found for dedicated bias‑detection tooling. | NA |
| Ethical Safeguards | OM1’s security and platform pages outline strict HIPAA‑compliant safeguards, need‑to‑know access, AWS‑based security, and recommendations that user organizations implement additional approval controls for critical transactions, as well as responsibilities to report control‑environment changes, indicating a shared‑responsibility governance model. OM1’s Registries Center of Excellence commits to regulatory compliance, rigorous QC, and data‑governance practices for fit‑for‑purpose data, but there is no explicit mention of AI‑specific governance features such as configurable use‑case restrictions, formal human‑in‑the‑loop approval gates for AI outputs, or consent‑management tooling built into the platform (beyond standard consent and data‑use agreements at participating sites). No public documentation found for dedicated AI‑ethical safeguard modules beyond privacy, security, and regulatory‑compliance frameworks. | NA |
Risks & Limitations: OM1
-
Predictive performance depends on the quality, completeness and representativeness of clinical data (claims, EHR, device feeds); gaps or biased cohorts can reduce model validity.
-
Outputs are decision-support only; clinicians, researchers and ops teams must validate recommendations and retain override authority before action.
-
Integration with proprietary EHRs, data warehouses, or site-specific pipelines may require IT mapping, middleware and governance effort.
-
Regulatory, privacy and compliance review may be required when using AI outputs to inform trial design, patient selection, or care decisions; maintain audit trails and documentation.
-
Model drift and distribution shifts (new care patterns, coding changes, or device updates) can degrade performance—plan for continuous monitoring and periodic retraining.
-
Limited explainability for some model outputs can hinder clinician trust and complicate root-cause analyses; include provenance and rationale where possible.
-
False positives/negatives may drive unnecessary interventions or missed signals—threshold tuning, clinical workflows, and capacity planning are essential to manage operational impact.
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
